Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.

dexamethasone sodium phosphate (AVM0703) - AVM Biotechnology

https://meetings.asco.org/abstracts-presentations/232719/

Lihua Elizabeth Budde; Theresa Deisher; Don A. Stevens; Gary J. Schiller; Stefano R. Tarantolo; Ryan C. Ramaekers; Peter Jarzyna; Spencer Sawas; Sandeep Mittal

Apr 25, 2024